Simone Beattie, PA
Surgical · Baltimore, MDNPI 1326680125
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,644 of the $6,755 with a category attached, or 83.6%. It is spread thinly across 31 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,662 and has fallen 97.7% since, to $83 in 2025. Among surgical clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 246 payments — averaging $27.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$1K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$508
- Sanofi$467
- Grifols USA, LLC$452
- GSK$443
- plus $2K from 25 others
What the payments were for
- Travel & lodging$94314%
- Food & beverage$5,64484%
- Education$1672%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 10 | $1,396 |
| AstraZeneca(2 entities) | 57 | $1,113 |
| Regeneron Healthcare Solutions, Inc. | 19 | $508 |
| Sanofi | 24 | $467 |
| Grifols USA, LLC | 22 | $452 |
| GSK | 21 | $443 |
| Bayer | 9 | $303 |
| AbbVie | 8 | $252 |
| Harmony Biosciences LLC | 7 | $250 |
| Boehringer Ingelheim | 8 | $233 |
| United Therapeutics Corporation | 8 | $148 |
| Actelion Pharmaceuticals US, Inc. | 5 | $142 |
| Baxter Healthcare | 7 | $141 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Genentech USA, Inc. | 3 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $82 |
| Novartis | 4 | $81 |
| Amgen | 4 | $79 |
| Mylan Specialty L.p. | 3 | $65 |
| Astellas Pharma US Inc | 3 | $62 |
| Merck | 3 | $59 |
| Electromed, Inc. | 5 | $55 |
| Mallinckrodt Hospital Products Inc. | 2 | $46 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $43 |
| Boston Scientific | 1 | $35 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Bard Peripheral Vascular, Inc. | 1 | $21 |
| Pharming Healthcare, Inc. | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Philips North America LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,755 in reported general payments places this provider in the 95th percentile of 277 surgical providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 124 | $91,723 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $25,045 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $17,435 |
| Spiriva RespimatTiotropium Bromide | 15 | $9,936 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 57 | $9,786 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $9,457 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $9,120 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $6,069 |
| Wixela InhubFluticasone Propion/Salmeterol | 61 | $5,361 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $4,788 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 171 | $4,218 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,069 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 25 | $3,954 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 20 | $1,471 |
| Montelukast Sodium | 46 | $737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $443 | $123,403189 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,113 | $29,11452 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $233 | $19,05634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 277 surgical providers in Maryland.
Other surgical in Baltimore
- Erika NigamBaltimore$8K
- Tara MorrisBaltimore$7K
- Cairo KeenanBaltimore$4K
- Rakhmin KhoshayevBaltimore$4K
- Olga Duclos-LasnierBaltimore$4K
- Rashel CastelgrandeBaltimore$3K
- Samantha HammockBaltimore$2K
- Nam PhamBaltimore$2K
- Lindsey ManosBaltimore$2K
- Amaris JamesBaltimore$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.